Study #2022-0174
Phase Ib trial of the KRASG12C inhibitor Adagrasib (MRTX849) in KRAS G12C mutant metastatic pancreatic cancer patients.
MD Anderson Study Status
Not Accepting
Treatment Agent
MRTX849
Description
To learn if the investigational study drug, adagrasib (also called MRTX849), can help to control pancreatic cancer that has a KRAS G12 mutation. The safety and possible effects of adagrasib will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Pancreatic Cancer
Study phase:
Phase I
Physician name:
Dan Zhao
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-499-2252
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.